Cashu
NTT DATA Acquires SPRO IT Solutions to Boost SAP in Agribusiness Sector
about 1 month ago
Stocks
Health Care
spro
Spero Therapeutics
NASDAQ: SPRO
-0.02 (-0.78%)
2.55
USD
At close at Jan 09, 21:36 UTC
Overview
Loading chart...
Key Stats
Market Cap
144.63M
Dividend Yield
0.00%
P/E Ratio
-3.30
EPS
-1.27
Revenue
47.98M
Avg. Volume
288.39K
About
What does SPRO do?
Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.